News - Vivus, Arena Pharmaceuticals

Filter

Popular Filters

1 to 25 of 54 results

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

20-11-2013

Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNovo NordiskPharmaceuticalVictoza

Eisai to double Belviq sales force by December

Eisai to double Belviq sales force by December

15-10-2013

Eisai’s US subsidiary will increase its force for the obesity drug Belviq to around 400 representatives…

Arena PharmaceuticalsBelviqEisaiManagementMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Auxilium gains rights to Vivus ED drug for USA and Canada

11-10-2013

Auxilium Pharmaceuticals has signed an agreement with fellow USA-based Vivus providing Auxilium with…

Auxilium PharmaceuticalsLicensingMen's HealthNorth AmericaPharmaceuticalStendraVivus

Vivus obesity drug reduces progression to type 2 diabetes in high-risk overweight patients

10-10-2013

New data published on-line in Diabetes Care, today Care demonstrating positive effects of USA-based Vivus’…

DiabetesMetabolicsPharmaceuticalQsymiaResearchVivus

Eisai's launch plan for obesity drug Belviq in USA enters consumer phase

16-09-2013

The US launch campaign by Japanese drug major Eisai (TYO: 4523) of the weight-loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Market for obesity therapies to reach a value of $2.6 billion in 2019

16-09-2013

The global obesity therapeutics market has been forecast to increase at a compound annual growth rate…

GlobalMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

Anti-obesity drug market to more than triple by 2019; report

05-09-2013

The anti-obesity drug market, which is dominated by off-patent orlistat, Swiss pharma major Roche's (ROG:…

Markets & MarketingMetabolicsorlistatPharmaceuticalQsymiaRocheVivusXenical

Resubmission expected for Orexigen's obesity drug Contrave

29-08-2013

US biopharma company Orexigen Therapeutics (Nasdaq: OREX) has announced that the Light Study independent…

Arena PharmaceuticalsBelviqContraveGastro-intestinalsNorth AmericaOrexigen TherapeuticsPharmaceuticalQnexaRegulationVivus

Sanofi to produce avanafil for Vivus

02-08-2013

US drugmaker Vivus (Nasdaq: VVUS) says it has entered into a commercial supply agreement with French…

avanafilMen's HealthPharmaceuticalProductionSanofiSpedraVivus

Focus on weight-loss drugs in Latin America

23-07-2013

The increasing prevalence of obesity in Brazil and Mexico is encouraging its governments to consider…

Abbott LaboratoriesArena PharmaceuticalsBelviqByettaGastro-intestinalsHealthcareJohnson & JohnsonNovo NordiskPharmaceuticalQsymiaReductilRocheSouth AmericaTopamaxVictozaVivusXenical

Vivus reaches agreement with First Manhattan and appoints new board

19-07-2013

A truce has been called between US drugmaker Vivus (Nasdaq: VVUS) and its top investor First Manhattan…

ManagementNorth AmericaPharmaceuticalVivus

Law suit threat for Vivus over battle for shareholders' votes

17-07-2013

The battle has heated up between US drugmaker Vivus (Nasdaq: VVUS) and its top investor First Manhattan…

FinancialNorth AmericaPharmaceuticalQsymiaVivus

Vivus offers a compromise to end the proxy contest

14-07-2013

US drugmaker Vivus (Nasdaq: VVUS) said on Saturday (July 13) that it had communicated to Sam Colin and…

ManagementPharmaceuticalQsymiaVivus

European approval for Vivus' ED drug Spedra

27-06-2013

The European Commission yesterday (June 26) has granted marketing authorization for USA-based Vivus'…

avanafilEuropeMen's HealthPharmaceuticalRegulationReproductiveSpedraVivus

It's official: "obesity is a disease," says AMA

20-06-2013

The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Arena/Eisai's Belviq at last to launch in the USA

07-06-2013

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) says that its long-awaited weight loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Arena and Eisai finally get DEA scheduling for obesity drug Belviq

08-05-2013

The long wait to get obesity drug Belviq (lorcaserin) to the US market, where it was approved by the…

Arena PharmaceuticalsBelviqEisaiMetabolicsNorth AmericaPharmaceuticalRegulation

Arena Pharma pulls EU application for Belviq; posts 1st-qtr results

06-05-2013

As part of an update on its activities and first-quarter financial results report, USA-based Arena Pharmaceutical…

Arena PharmaceuticalsBelviqEisaiEuropeFinancialMetabolicsPharmaceuticalRegulation

Vivus rises as FDA eases restrictions on diet pill Qsymia

17-04-2013

USA drugmaker Vivus' (Nasdaq: VVUS) shares rose as much as 11% by traded up 5% at $11.69, after the company…

MetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Vivus announces new discount program for obesity drug Qsymia

06-03-2013

US drugmaker Vivus (Nasdaq: VVUS) has announced a new program offering eligible patients a discount on…

Markets & MarketingMetabolicsNorth AmericaPharmaceuticalPricingQsymiaVivus

EMA confirms negative view on Vivus' obesity drug Qsiva after appeal

22-02-2013

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dealt a blow to…

EuropeMetabolicsPharmaceuticalQsivaQsymiaRegulationVivus

1 to 25 of 54 results

Company Spotlight

Fibrotech

Fibrotech

Back to top